Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses

Context: Pheochromocytomas and paragangliomas (PPGLs) with pathogenic mutations in the succinate dehydrogenase subunit B (SDHB) are associated with a high metastatic risk. Somatostatin receptor 2 (SSTR2)-dependent imaging is the most sensitive imaging modality for SDHB-related PPGLs, suggesting that SSTR2 expression is a significant cell surface therapeutic biomarker of such tumors.

Objective: Exploration of the relationship between SSTR2 immunoreactivity and SDHB immunoreactivity, mutational status, and clinical behavior of PPGLs. Evaluation of SSTR-based therapies in metastatic PPGLs.

Methods: Retrospective analysis of a multicenter cohort of PPGLs at 6 specialized Endocrine Tumor Centers in Germany, The Netherlands, and Switzerland. Patients with PPGLs participating in the ENSAT registry were included. Clinical data were extracted from medical records, and immunohistochemistry (IHC) for SDHB and SSTR2 was performed in patients with available tumor tissue. Immunoreactivity of SSTR2 was investigated using Volante scores. The main outcome measure was the association of SSTR2 IHC positivity with genetic and clinical-pathological features of PPGLs.

Results: Of 202 patients with PPGLs, 50% were SSTR2 positive. SSTR2 positivity was significantly associated with SDHB- and SDHx-related PPGLs, with the strongest SSTR2 staining intensity in SDHB-related PPGLs (P = .01). Moreover, SSTR2 expression was significantly associated with metastatic disease independent of SDHB/SDHx mutation status (P < .001). In metastatic PPGLs, the disease control rate with first-line SSTR-based radionuclide therapy was 67% (n = 22, n = 11 SDHx), and with first-line "cold" somatostatin analogs 100% (n = 6, n = 3 SDHx).

Conclusion: SSTR2 expression was independently associated with SDHB/SDHx mutations and metastatic disease. We confirm a high disease control rate of somatostatin receptor-based therapies in metastatic PPGLs.

Citing Articles

SDHB-Associated Pheochromocytomas: What is Their Clinical Behavior?.

Szabo Yamashita T, Tame-Elorduy A, Skefos C, Varghese J, Habra M, Fisher S Ann Surg Oncol. 2024; 31(13):9007-9013.

PMID: 39382746 DOI: 10.1245/s10434-024-16120-z.

Peptide-guided adaptor-CAR T-Cell therapy for the treatment of SSTR2-expressing neuroendocrine tumors.

Pellegrino C, Favalli N, Volta L, Benz R, Puglioli S, Bassi G Oncoimmunology. 2024; 13(1):2412371.

PMID: 39376579 PMC: 11457607. DOI: 10.1080/2162402X.2024.2412371.

The heterobivalent (SSTR2/albumin) radioligand [Cu]Cu-NODAGA-cLAB4-TATE enables efficient somatostatin receptor radionuclide theranostics.

Ullrich M, Wodtke R, Brandt F, Freudenberg R, Kotzerke J, Richter S Theranostics. 2024; 14(14):5371-5387.

PMID: 39310112 PMC: 11413788. DOI: 10.7150/thno.100091.

[Advance in HIF expression and immune microenvironment in pseudohypoxic HNPGL].

Zhang B, Lou Z, Wang J, Hu Y, Chen Z Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2024; 38(9):823-829.

PMID: 39193740 PMC: 11839587. DOI: 10.13201/j.issn.2096-7993.2024.09.009.

Immunohistochemical Profiling of SSTR2 and HIF-2α with the Tumor Microenvironment in Pheochromocytoma and Paraganglioma.

Uchihara M, Tanabe A, Kojima Y, Shimoi T, Maeshima A, Umamoto K Cancers (Basel). 2024; 16(12).

PMID: 38927897 PMC: 11201597. DOI: 10.3390/cancers16122191.

References

Vyakaranam A, Crona J, Norlen O, Granberg D, Garske-Roman U, Sandstrom M . Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with Lu-DOTATATE. Cancers (Basel). 2019; 11(7). PMC: 6678507. DOI: 10.3390/cancers11070909. View

Rinke A, Auernhammer C, Bodei L, Kidd M, Krug S, Lawlor R . Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?. Gut. 2021; 70(9):1768-1781. DOI: 10.1136/gutjnl-2020-321300. View

Nastos K, Cheung V, Toumpanakis C, Navalkissoor S, Quigley A, Caplin M . Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas. J Surg Oncol. 2017; 115(4):425-434. DOI: 10.1002/jso.24553. View

Volante M, Brizzi M, Faggiano A, La Rosa S, Rapa I, Ferrero A . Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol. 2007; 20(11):1172-82. DOI: 10.1038/modpathol.3800954. View

Luchetti A, Walsh D, Rodger F, Clark G, Martin T, Irving R . Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis. Int J Endocrinol. 2015; 2015:138573. PMC: 4390106. DOI: 10.1155/2015/138573. View

Papathomas T, Oudijk L, Persu A, Gill A, van Nederveen F, Tischler A . SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Mod Pathol. 2015; 28(6):807-21. DOI: 10.1038/modpathol.2015.41. View

Patel Y . Somatostatin and its receptor family. Front Neuroendocrinol. 1999; 20(3):157-98. DOI: 10.1006/frne.1999.0183. View

Van Essen M, Krenning E, de Jong M, Valkema R, Kwekkeboom D . Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol. 2007; 46(6):723-34. DOI: 10.1080/02841860701441848. View

Forrer F, Riedweg I, Maecke H, Mueller-Brand J . Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging. 2008; 52(4):334-40. View

10.

Villaume K, Blanc M, Gouysse G, Walter T, Couderc C, Nejjari M . VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway. Neuroendocrinology. 2010; 91(3):268-78. DOI: 10.1159/000289569. View

11.

Tonyukuk V, Emral R, Temizkan S, Sertcelik A, Erden I, Corapcioglu D . Case report: patient with multiple paragangliomas treated with long acting somatostatin analogue. Endocr J. 2003; 50(5):507-13. DOI: 10.1507/endocrj.50.507. View

12.

Puranik A, Kulkarni H, Singh A, Baum R . Peptide receptor radionuclide therapy with (90)Y/ (177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours). Eur J Nucl Med Mol Imaging. 2015; 42(8):1223-30. DOI: 10.1007/s00259-015-3029-2. View

13.

Lenders J, Kerstens M, Amar L, Prejbisz A, Robledo M, Taieb D . Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020; 38(8):1443-1456. PMC: 7486815. DOI: 10.1097/HJH.0000000000002438. View

14.

Pamporaki C, Prodanov T, Meuter L, Berends A, Bechmann N, Constantinescu G . Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma. Eur J Cancer. 2022; 169:32-41. DOI: 10.1016/j.ejca.2022.03.032. View

15.

Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H . Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011; 29(17):2416-23. DOI: 10.1200/JCO.2010.33.7873. View

16.

Taieb D, Jha A, Treglia G, Pacak K . Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr Relat Cancer. 2019; 26(11):R627-R652. PMC: 7002202. DOI: 10.1530/ERC-19-0165. View

17.

Darr R, Nambuba J, Del Rivero J, Janssen I, Merino M, Todorovic M . Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. Endocr Relat Cancer. 2016; 23(12):899-908. PMC: 5096964. DOI: 10.1530/ERC-16-0231. View

18.

Satapathy S, Mittal B, Bhansali A . 'Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis'. Clin Endocrinol (Oxf). 2019; 91(6):718-727. DOI: 10.1111/cen.14106. View

19.

Taieb D, Hicks R, Hindie E, Guillet B, Avram A, Ghedini P . European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019; 46(10):2112-2137. PMC: 7446938. DOI: 10.1007/s00259-019-04398-1. View

20.

Ullrich M, Liers J, Peitzsch M, Feldmann A, Bergmann R, Sommer U . Strain-specific metastatic phenotypes in pheochromocytoma allograft mice. Endocr Relat Cancer. 2018; 25(12):993-1004. PMC: 6176113. DOI: 10.1530/ERC-18-0136. View